AR113756A1 - Variantes porcinas de g-csf y sus usos - Google Patents

Variantes porcinas de g-csf y sus usos

Info

Publication number
AR113756A1
AR113756A1 ARP180102924A ARP180102924A AR113756A1 AR 113756 A1 AR113756 A1 AR 113756A1 AR P180102924 A ARP180102924 A AR P180102924A AR P180102924 A ARP180102924 A AR P180102924A AR 113756 A1 AR113756 A1 AR 113756A1
Authority
AR
Argentina
Prior art keywords
csf
variants
porcine
pigs
treating
Prior art date
Application number
ARP180102924A
Other languages
English (en)
Original Assignee
Ambrx Inc
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc, Elanco Us Inc filed Critical Ambrx Inc
Publication of AR113756A1 publication Critical patent/AR113756A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a variantes del factor estimulante de colonias de granulocitos porcinos (pG-CSF). Las variantes de pG-CSF son útiles en el tratamiento de infecciones bacterianas en cerdos. Se describen métodos de tratamiento de cerdos.
ARP180102924A 2017-10-11 2018-10-10 Variantes porcinas de g-csf y sus usos AR113756A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570877P 2017-10-11 2017-10-11

Publications (1)

Publication Number Publication Date
AR113756A1 true AR113756A1 (es) 2020-06-10

Family

ID=66101096

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102924A AR113756A1 (es) 2017-10-11 2018-10-10 Variantes porcinas de g-csf y sus usos

Country Status (13)

Country Link
US (2) US11578111B2 (es)
EP (1) EP3694535A4 (es)
JP (1) JP7046173B2 (es)
KR (2) KR102619071B1 (es)
CN (1) CN111565736B (es)
AR (1) AR113756A1 (es)
AU (2) AU2018348138A1 (es)
BR (1) BR112020007037A2 (es)
CA (1) CA3077215A1 (es)
MX (1) MX2020003742A (es)
RU (1) RU2020113060A (es)
TW (1) TWI820046B (es)
WO (1) WO2019075053A1 (es)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
WO1989010932A1 (en) * 1988-05-13 1989-11-16 Amgen Inc. Compositions and method for treating or preventing infections in animals
EP0447523A4 (en) * 1989-10-10 1991-11-27 Amgen Inc. Compositions and methods for treating or preventing infections in canine and feline animals
AU3515001A (en) * 1993-01-28 2001-06-28 Amgen, Inc. G-CSF analog compositions
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
RU2273645C9 (ru) * 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
CA2452540A1 (en) * 1996-10-15 1998-04-23 Amgen Inc. Keratinocyte growth factor-2 products
EP1144998A3 (en) * 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
EA200400067A1 (ru) 1999-01-29 2004-04-29 Эмджен Инк. Конъюгаты гксф
US7323174B1 (en) * 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
CN101426511A (zh) * 2001-06-22 2009-05-06 法马西亚公司 化学修饰的祖细胞生成素连接物
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
BR0213402A (pt) * 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
JP2006526016A (ja) * 2003-05-09 2006-11-16 シエーリング アクチエンゲゼルシャフト 炎症性呼吸器疾患の治療
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
CN101014616A (zh) * 2004-07-26 2007-08-08 埃斯特瑞恩有限公司 接头分子
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
JP4788646B2 (ja) * 2007-04-26 2011-10-05 トヨタ自動車株式会社 蓄電装置及び車両
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
EP2185583A2 (en) * 2007-08-03 2010-05-19 Asterion Limited Granulocyte colony stimulating factor
AU2013202836B8 (en) 2008-07-23 2015-07-30 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
JP5680534B2 (ja) * 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
WO2010096446A1 (en) * 2009-02-17 2010-08-26 Marc Fisher Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
JP5657698B2 (ja) * 2010-01-19 2015-01-21 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型顆粒球コロニー刺激因子結合体の液剤
WO2011163460A1 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
AR083006A1 (es) * 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA2838246C (en) * 2011-06-13 2018-07-10 Csl Limited Antibodies against g-csfr and uses thereof
US9573987B2 (en) * 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
JP2015518470A (ja) * 2012-03-26 2015-07-02 プロニュートリア・インコーポレイテッドＰｒｏｎｕｔｒｉａ， Ｉｎｃ． 栄養タンパク質および方法

Also Published As

Publication number Publication date
RU2020113060A (ru) 2021-11-12
RU2020113060A3 (es) 2021-12-27
KR102619071B1 (ko) 2023-12-27
US20210054039A1 (en) 2021-02-25
CA3077215A1 (en) 2019-04-18
KR20200066628A (ko) 2020-06-10
US20230340051A1 (en) 2023-10-26
CN111565736A (zh) 2020-08-21
EP3694535A1 (en) 2020-08-19
EP3694535A4 (en) 2021-07-28
AU2021204727B2 (en) 2023-02-09
WO2019075053A1 (en) 2019-04-18
KR20220150432A (ko) 2022-11-10
JP7046173B2 (ja) 2022-04-01
KR102461760B1 (ko) 2022-10-31
AU2021204727A1 (en) 2021-08-05
BR112020007037A2 (pt) 2020-11-17
MX2020003742A (es) 2020-10-28
TWI820046B (zh) 2023-11-01
US11578111B2 (en) 2023-02-14
TW201928058A (zh) 2019-07-16
JP2020536935A (ja) 2020-12-17
AU2018348138A1 (en) 2020-04-23
CN111565736B (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CO2020004233A2 (es) Vesículas extracelulares bacterianas
CO2019006675A2 (es) Suministro de proteínas basado en bacterias con virulencia atenuada
PH12016501512B1 (en) Treatment for resistant acne
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CL2018002774A1 (es) Detección de infección microbiana en heridas
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
ECSP15048555A (es) Heterociclos bicíclicos como inhibidores de fgfr
AR093310A1 (es) Composiciones y metodos para mejorar el crecimiento de las plantas
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
ZA202002093B (en) Antibacterial compounds
CO2020016131A2 (es) Agonistas de tlr7
CO2017010271A2 (es) Archaebacteria en alimento para animales bioactivo, método para hacer la composición y métodos que emplean la composición
DK3285787T3 (da) Behandling af bakterieinfektioner i akvakultur
AR113514A1 (es) Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales
AR113756A1 (es) Variantes porcinas de g-csf y sus usos
CO2022008835A2 (es) Agonistas del tlr7
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
RU2014125665A (ru) Способ наружного лечения микозов кожи
CO2019006311A2 (es) N-acetilcisteína para su uso como agente antibacteriano
CL2018000336A1 (es) Composición para el tratamiento de la mucosidad en las branquias de los peces
AR124003A1 (es) Inducción de efectos inmunitarios usando bacterias veillonella parvula
AR114246A1 (es) Composición y métodos para tratar cáncer y trastornos inmunes usando bacterias veillonella
RU2015118633A (ru) Тени бактерий L. casei 577 для стимулирования врожденного иммунного ответа и их применение